Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Bioptimus is developing multimodal and multiscale AI pathology models for biomarker and drug treatment prediction.
Rights and permissions
About this article
Cite this article
Eisenstein, M. Editor’s pick: Bioptimus. Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03345-4
-
Published:
-
Version of record:
-
DOI: https://doi.org/10.1038/s41587-026-03345-4
